“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
DaVita Clinical Research investigates the presence of COVID-19 antibodies and genetic contributions to patients’ severity
DENVER, August 20, 2020 / PRNewswire / – DaVita Clinical Research (DCR), a subsidiary of DaVita Inc., has begun enrolling in two clinical trials to examine how COVID-19 affects other people with end-stage kidney disease (ESKD) who are dialing lately.
“As a new virus, there are still many things the medical network doesn’t know about COVID-19,” said Dr. Jeff Giullian, DaVita’s medical director. “With our resources to conduct this research, we hope to bring meaningful knowledge to a global effort. We look forward to sharing our findings on how the virus behaves in a medically vulnerable population to drive further innovation.”
In the first study, Registry of Sustained Immunity to COVID-19 in ESKD patients, researchers are investigating how the presence of COVID-19 antibodies would possibly influence long-term viral infection and prospective immunity in dialysis patients at DaVita dialysis centers. Participants will be monitored in autumn and winter for 4 months to read about increased exposure to COVID-19 and any progression of the disease.
The study at the moment, the progress of COVID-19 in end-stage renal disease, examines the associations between genetic markers and the severity of COVID-19 symptoms in RTD patients. Study participants are stratified into two groups: patients diagnosed with positive for COVID-19 and patients with no history of COVID-19 who tested positive for immunoglobulin antibody G (IgG). Researchers point to associations between genetic differences and the severity of COVID-19 disease.
“Our researchers seek to help understand the effect COVID-19 has on a population of patients who are most threatened by underlying medical conditions,” said Amy Young, VICE President of DCR. “These studies are vital for older people to expect long-term COVID-19 outbreaks, minimize infections, and ultimately save lives.”
According to the U.S. Kidney Data System, approximately 524,000 other people in the United States suffer from ESKD requiring dialysis care. These patients are among those most at risk of COVID-19 due to underlying fitness disorders that compromise their immune system. Recent studies have also connected severe cases of COVID-19 with kidney complications, adding a greater threat of acute kidney injury that requires ongoing kidney replacement therapy.
The effects of the two COVID-19 DCR studies are expected to be submitted for publication in early 2021.
To be more informed about DCR, DaVitaClinicalResearch.com.
About DaVita Clinical Research DaVita Clinical Research (DCR), a subsidiary of DaVita Inc., is daVita’s branch of studies. DCR innovates through retrospective studies aimed at clinical outcomes. DCR assists pharmaceutical and medical device corporations in the design, recruitment and conduct of clinical trials through its network of kidney study sites. For more information about DCR, visit DaVitaClinicalResearch.com.
About DaVita Inc. DaVita (NYSE: DVA) is a healthcare provider that aims to transform care delivery into the quality of life of patients around the world. The company is one of the largest providers of kidney care facilities in the United States and has been a leader in innovation and clinical quality for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end-stage renal failure. DaVita is committed to bold, patient-centered care models, implementing the latest technologies and evolving into built-in care offerings for everyone. As a result of these efforts, DaVita has also become the country’s largest home dialysis provider. As of June 30, 2020, DaVita served 205,300 patients at 2,795 outpatient dialysis centers in the United States. The company also operated 287 outpatient dialysis centers in ten countries around the world. DaVita has reduced hospitalizations, mortality and worked collaboratively to drive the kidney care industry to adopt fair, high-quality popular care for all patients around the world. For more information, visit DaVita.com/About.
Forward-looking statements Certain statements contained in this press release are forward-looking statements relating to dangers and uncertainties. These forward-looking statements are based on the existing expectations of the administration. There are a number of points that can cause the actual effects to differ materially, adding the known hazards in our filings through the U.S. Securities and Exchange Commission. DaVita disclaims any legal responsibility to update the forward-looking statements contained in this press release.
Press contact: Halie [email protected] (303) 550-6349
Check the content to download the media: http://www.prnewswire.com/news-releases/clinical-research-trials-underway-to-study-covid-19-impact-on-dialysis-patients-301115357.html
FUENTE DaVita Clinical Research